A health law expert has examined the LillyDirect platform, which now facilitates dispensing of the pharmaceutical company's own GLP1 medicine in Australia.

He talks through the regulations that apply to this model to see how it stacks up. 

Norman Swan is a director of a company that has a share in an online pharmacy business.

Guest/s

  • Dr Christopher Rudge, lecturer at Sydney Law School, and Deputy Director of Sydney Health Law 

References

Podden och tillhörande omslagsbild på den här sidan tillhör ABC Australia. Innehållet i podden är skapat av ABC Australia och inte av, eller tillsammans med, Poddtoppen.